Affordable Access

deepdyve-link
Publisher Website

Pharmacokinetics and absolute oral bioavailability of meloxicam in guinea pigs (Cavia porcellus)

Authors
  • Moeremans, Ilse
  • Devreese, Mathias
  • De Baere, Siegrid
  • Croubels, Siska
  • Hermans, Katleen
Publication Date
Jan 01, 2019
Identifiers
DOI: 10.1016/j.vaa.2018.11.011
OAI: oai:archive.ugent.be:8624649
Source
Ghent University Institutional Archive
Keywords
Language
English
License
Unknown
External links

Abstract

Objective: To investigate the pharmacokinetics and absolute oral bioavailability of meloxicam in guinea pigs. Study design: Prospective crossover study. Animals: A group of six healthy male Dunkin Hartley guinea pigs. Methods: A single dose of meloxicam (1.5 mg kg(-1)) was administered orally and intravenously (IV) to six healthy male guinea pigs. A wash-out period of 48 hours was taken into account between administrations (oral and IV) in the same animal. Blood was sampled through a central venous catheter before administration (t = 0 hours) and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, 24 and 28 hours post administration. After centrifugation, plasma concentrations of meloxicam were measured by high-performance liquid chromatography with UV detection, and pharmacokinetic parameters were calculated using noncompartmental analysis. Results: Meloxicam in guinea pigs exhibited a moderate absorption rate after oral dosing (time to maximal plasma concentration 3.7 +/- 1.7 hours) and maximal plasma concentration was 0.92 +/- 0.30 mg mL(-1). After IV administration, total body clearance and volume of distribution were 0.13 +/- 0.04 and 0.72 +/- 0.36 L kg(-1), respectively. Terminal half-life was 3.7 +/- 0.7 hours and 3.5 +/- 1.1 hours after IV and oral administration, respectively. Body extraction ratio was 0.0087 and mean absorption time was 3.8 +/- 1.7 hours. The absolute oral bioavailability was 0.54 +/- 0.14 in unfasted guinea pigs. Conclusions and clinical relevance: This study reported the pharmacokinetics of meloxicam in guinea pigs. Studies concerning efficacy and safety are the next step towards a rational use of this drug in guinea pigs.

Report this publication

Statistics

Seen <100 times